logo
logo
Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ•CRBP
CEO: Dr. Yuval Cohen Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2014-10-27
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
連絡先情報
500 River Ridge Drive, Norwood, MA, 02062, United States
617-963-0100
www.corbuspharma.com
時価総額
$94.77M
PER (TTM)
-1.4
34.3
配当利回り
--
52週高値
$20.56
52週安値
$4.64
52週レンジ
18%
順位65Top 96.0%
1.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$1.90+65.22%
直近4四半期の推移

フリーCF

-$15.55M+11.53%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Cash Position Strengthened Total cash, equivalents, restricted cash reached $27.7 M at September 30, 2025, up $9.8 M from year-end 2024.
Major Equity Financing Closed Completed $75.0 M gross proceeds public offering in November 2025, securing operating runway for clinical development.
R&D Spending Surges Research and development expenses grew 121% to $51.7 M for nine months, supporting CRB-701 and CRB-601 trials.

リスク要因

Accelerating Net Loss Net loss widened to $(58.0) M for nine months, nearly doubling prior year's $(30.7) M loss due to increased spending.
High Operating Expense Growth Total operating expenses grew 75% to $63.3 M for nine months, driven primarily by escalating clinical trial costs.
Pre-Revenue Dependency Company remains clinical-stage, generating zero revenue, dependent on external capital to fund operations and development.
Equity Value Erosion Total stockholders' equity decreased to $92.1 M; future financing may result in significant dilution to existing shareholders.

見通し

CRB-701 Registrational Planning Expect to engage FDA mid-2026 regarding the design of a registrational study for the lead oncology candidate CRB-701.
Obesity Trial Initiation Obesity candidate CRB-913 expected to initiate a Phase 1b dose-range finding study in obese non-diabetic individuals in Q4 2025.
Future Capital Requirements Requires significant additional capital to fund ongoing pre-clinical and clinical trials for all three pipeline product candidates.

同業比較

売上高 (TTM)

Genfit S.A.GNFT
$126.71M
+9.8%
Alector, Inc.ALEC
$69.05M
+12.3%
Codexis, Inc.CDXS
$52.93M
-17.9%

粗利益率 (最新四半期)

Genfit S.A.GNFT
100.0%
+0.0pp
Alector, Inc.ALEC
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PEPG$442.74M-2.3-84.1%9.2%
FBRX$402.24M-11.0-75.6%0.0%
GNFT$398.37M-9.2-63.7%64.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月10日
|
EPS:-$1.78
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.90+65.2%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.44-59.4%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.39-43.3%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月11日|
    売上高: $0.00+0.0%
    |
    EPS: $-3.68+64.3%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.15-49.3%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-3.55+73.2%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-2.45-42.2%
    不明

  • Form 10-K/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月20日|
    売上高: $0.00+0.0%
    |
    EPS: $-10.31-1.6%
    不明